Admissions:
None
Delistings:
None
Potential** Initial Public Offerings:
Media Speculation:
28 April 2025: Media reports Waves Audio, headquartered in Tel Aviv, is planning a £300m London IPO. Waves Audio makes professional digital audio signal processing technology and audio effects used in recordings, mixing, mastering, post-production, broadcasting, and live sound. It employs more than 200 people, and has a major international presence, including in Europe and the US. The Company, which is majority-owned by founders Meir Sha'ashua and Gilad Keren, is expected to raise money from the sale of new shares, although the details have yet to be finalised.
29 April 2025: Media reports that Metlen hoped to take advantage of a recent rule change that would allow it to trade its share in London in Euros. It aims to secure a primary listing in London this year and retain a secondary listing in Athens, where it is traded at present with a market capitalisation of EUR6.15bn, which would be enough for it to enter the FTSE 100. Metlen has interests including aluminium production, renewable power generation, and household energy supply.
Alt Resources 6.5p £3m (ALTR.L)
Further to the announcement on 24 February 2025, the mining royalty and streaming company announced that the long stop date of 18 April 2025 to acquire a near-producing gold mining royalty has now passed. Therefore, the Company is no longer moving forward with the Proposed Acquisition. However, the Company is progressing other opportunities in its pipeline of activities. Completing one or more of the Pipeline Acquisitions will be subject to certain conditions, including, inter alia, due diligence, legal documentation, and fundraising. The Company still plans to seek admission of the Company's entire issued and to be issued share capital to trading on AIM concurrent with the completion of a new proposed acquisition.
Clean Power Hydrogen 5.75p £20.4m (CPH2.L)
The UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser, today announced its results for the year ended 31 December 2024. The company recorded progress towards the commercial roll out of CPH2's MFE technology, with the first customer acceptance and validation of the Company's unique scaled electrolyser technology marking the transition from R&D to the Commerciality Phase. The technology successfully completed the Factory Acceptance Test of the MFE110, demonstrating that it works safely at scale. The company signed a significant Licence Agreement with Hidrigin to manufacture up to 2GW of MFE electrolysers over a 20-year period, alongside signing a Sales Contract for the delivery of a MFE220 unit. Year-end cash and term deposits was £0.3m (2023: £8.5m). Post-year end the Company successfully completed an equity fundraise, generating net proceeds of £5.7m.
Emmerson 2.35p £30.4m (EML.L)
The Moroccan focused potash development company today provided an update on the dispute with the Kingdom of Morocco in relation to the Khemisset Potash Project in Morocco. A Request for Arbitration has been submitted to the International Centre for Settlement of Investment Disputes, an arm of the World Bank with regard to various breaches, by the Government of Morocco and its Agents, of the Agreement between the United Kingdom and Morocco for the Promotion and Protection of Investments, which was signed on 30 October 1990 and entered into force on 14 February 2002. The company is bringing a claim for full compensation in respect of the Khemisset Potash Project which it had internally valued at $2.2b. All the legal costs in relation to the matter as well as a significant portion of G&A costs are to be funded through the $11.2m litigation funding facility confirmed in January 2025. Emmerson, through the Company's legal advisors Boies Schiller Flexner, are working on the formation of the arbitral tribunal and preparing a formal Memorial submission.
GenIP 31p £5.4m (GNIP.L)
The company providing GenAI analytic services to help organisations assess and commercialise new discoveries, announced the launch of a new AI-powered product and its first client for the new product, a 'Big Four' accountancy firm. The new AI-powered 'Competitive Intelligence Report' helps organisations identify and assess entities in specific technologies, providing insights for strategic decision-making on innovation, collaboration, and acquisitions. The report broadens GenIP's market reach, extending its applications beyond technology commercialisation. It serves businesses seeking competitive intelligence, universities mapping research priorities, and institutions exploring collaboration or acquisition prospects.
Ilika 37.5p £63m (IKA.L)
The independent solid-state battery technology company today announced that it has received confirmation from OEM and Tier 1 testing partners that its P1 Goliath prototypes perform to specification. Further to its RNS of May 2024 announcing commencement of testing of P1 prototype cells on behalf of, and subsequently by, commercial partners, the Company confirms that the suite of tests including cell formation protocol, measurement of energy capacity, charge rate, power delivery capability and accelerated cyclability have confirmed the specification of its P1 cells. Furthermore, the tests demonstrated good reproducibility across the batch and delivered the expected electrochemical signature. The tests were carried out under commercial agreements with confidentiality provisions designed to protect proprietary duty cycle protocols owned by the OEMs and Tier 1 companies.
Intercede Group 159p £92m (IGP.L)
The digital identity management company today announced the launch of its latest version of MyID CMS that enables the management of Passkeys with Microsoft Entra ID. Administrators can now use the credentials management system to seamlessly manage FIDO Passkeys on devices including the Yubico YubiKey family of products, that can then be used to securely authenticate to Entra ID protected resources. The solution enables organisations to use seamless, secure authentication processes by combining the strengths of the Intercede, Yubico, and Microsoft technology platforms.
Itaconix 103.5p £14m (ITX.L)
The innovator of plant-based specialty polymers used in everyday consumer products, provided an update on current trade developments. Trading for 2025 remains in line with the Board's expectations. US trade actions taken in recent weeks are expected to have a negative effect on production costs and positive impacts on US and European revenues. In addition, the Company is implementing selective price increases and supply chain cost reduction efforts to maintain profit margins. Expected outcomes remain subject to any new or revised trade actions.
Mycelx Technologies 23.5p £5.6m (MYX.L)
The clean water and clean air technology company, acknowledged the announcement by the United States Environmental Protection Agency regarding a comprehensive plan to tackle PFAS contamination, focusing on prevention, accountability, and support for affected communities. Key actions cited in the announcement include appointing a PFAS agency lead, developing effluent guidelines to prevent PFAS from entering water systems, enhancing scientific research and detection, and creating a liability framework to ensure polluters bear responsibility for the remediation costs. The company is of the view that the announcement will lead to increased activity and investment in the PFAS remediation market.
The Parkmead Group 14.75p £15.3m (PMG.L)
Further to the announcement on 12 December 2024, the company reports that all conditions relating to the sale of its wholly owned subsidiary, Parkmead Ltd, to Serica Energy Ltd have now been met and that the sale has therefore completed. Pursuant to the terms of the sale & purchase agreement, Parkmead has received a cash payment of approximately £7.3m on completion (inclusive of working capital adjustments). Parkmead will also receive a further £7.0m of additional firm cash consideration and up to £120m of contingent cash consideration. Beyond this sale of its UK North Sea offshore licences, Parkmead has retained 100% of its cash producing assets. These are all onshore and comprise its interests in several gas fields in the Netherlands and its wholly owned wind farm in Scotland.
Totally 1.5p £2.9m (TLY.L)
The frontline healthcare services, corporate fitness and wellbeing services across the UK and Ireland, makes a trading update FY March 2025. There is also a second announcement on a Strategic Review. Revenue expectations of £85.m and an EBITDA of £3.5m are reduced due to a combination of a slower than expected ramp up of a recent contract win and reduced operating margins. The Group’s current estimates indicate an EBITDA range of between £0m and £2m with exceptional costs of around £3.8m. There are further new contract wins over the coming months and the Group is profitable monthly. The Board is in the process of undertaking a comprehensive review and will consider strategic options including, selling subsidiaries, receiving strategic investment or undertaking a corporate action. There is likely to be an impairment of goodwill as part of this exercise.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
